Connect with us

Now

Egyptian museum calls for Rosetta Stone to be returned from UK after 200 years

Published

on

n Egyptian museum has renewed calls for the Rosetta Stone to be returned back to Egypt after more than 200 years in the British Museum.

The ancient slab, which is engraved with three languages and unlocked the secret of Egyptian hieroglyphs, has been a long-running source of tension between Cairo and London.

British soldiers captured the stone in 1801 after defeating Napoleon’s army in Egypt and transferred it to the British Museum, where it has long been the most-visited object.

Dr Tarek Tawfik, the director of the new Grand Egyptian Museum (GEM), said he was eager to see the Rosetta Stone back in Egypt.

“It would be great to have the Rosetta Stone back in Egypt but this is something that will still need a lot of discussion and co-operation,” Dr Tawfik told the Evening Standard.

He said he was involved in “vivid discussions” about possibly returning the Rosetta Stone to his own museum.

A British Museum spokeswoman said: “We have not received a request for the return of the Rosetta Stone from GEM.

“In April, British Museum director Hartwig Fischer and colleagues visited the galleries at GEM with Dr Tawfik, which will allow a stunning new display of pharaonic Egypt.”

Dr Tawfik suggested that virtual reality technology could be used to foster a compromise and allow “a way of co-operation and means of complementing each other between the museums”.

Egyptian officials have demanded the return of the Rosetta Stone for decades but have never succeeded in convincing the British Museum to hand it over.

The stone is engraved with an identical message in Ancient Greek, Demotic and Egyptian hieroglyphs, allowing 19th century scholars to translate the hieroglyphs.

A similar argument has played out over the Elgin Marbles, a series of Greek sculptures which were brought to the UK from Greece at around the same time as the Rosetta Stone and are also kept at the British Museum.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Now

AstraZeneca COVID-19 vaccine Shows 90% Effectiveness With No Serious Side Effects

Published

on

By

AstraZeneca announced today the effectiveness of its Covid-19 vaccine and it turned out to be around 90% effective with no serious side effects!

According to data from the late-stage trials in Britain and Brazil, the vaccine, which is developed by Oxford University, has shown 90% effectiveness after being administered as a a half dose followed by a full dose at least one month apart.

“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, Astra’s chief executive, said in a statement.

British Prime minister Boris Johnson said it was “incredibly exciting news the Oxford vaccine has proved so effective in trials.”

The next step now is for the company to start preparing regulatory submission of the data to authorities across the world that have a framework in place for conditional or early approval.

It will also seek an emergency use listing from the World Health Organization (WHO) to speed up availability in countries with low income. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal.

With both Oxford’s and Pfizer’s vaccines, we can be hopeful that the new year will come bearing good news!

Continue Reading

Now

Another Coronavirus Vaccine By Moderna Shows 94.5% Effectiveness!

Published

on

By

Yet another promising news for a Covid-19 vaccine has been announced! Moderna said today that its vaccine has shown 94.5% effectiveness in preventing the virus, according to an analysis of its clinical trial.

The biotech company made the announcement earlier today, giving us a dash of hope amidst this coronavirus scare.

The news follows the announcement made by Pfizer and BioNTech, who said their vaccine was more than 90% effective.

The results come from interim analyses of intensive clinical studies. The clinical trials of Moderna saw the participation of 30,000 volunteers. Half got two doses of the vaccine 28 days apart, half got two shots of a placebo on the same schedule.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, chief executive officer of Moderna, in a statement.

Both companies used the same technology in making the vaccines, which is a tech based on a molecule known as mRNA, or messenger RNA. That molecule contains genetic instructions for making proteins inside cells.

We hope that by the end of this year, we can rest assured that a vaccine can soon end this pandemic.

Continue Reading

Now

Hopes Rise As Pfizer Announces That Its COVID-19 Vaccine is 90% Effective

Published

on

By

Hope rises as pharmaceutical giant Pfizer announced that its COVID-19 vaccine has successfully prevented 90% of the virus, a promising result that exceeded experts’ expectations!

This analysis is based on 94 cases of infection with SARS-CoV-2, the virus responsible for causing COVID-19, among both the vaccinated and placebo groups. The results included data from 38,955 of the total 43,538 volunteers who enrolled.

This makes Pfizer the very first company to release results from its Covid-19 vaccine, these findings are a result of collected seven days after the second of Pfizer’s two-shot regimen.

 

 

Continue Reading
Event calender
Cinema calender

Cinema calender

Facebook

Fashion

Categories

Top Posts

Trending

X